We’ve partnered with IDBS, a Danaher company and one of the biggest providers of cloud software in biopharma. The short version: Alchemi’s AI agents can now work directly with the data sitting inside the IDBS Polar platform, across the drug development lifecycle.
Here’s why that matters.

The problem

Getting a regulatory filing ready is slow. CMC teams spend months pulling data together, writing reports, and piecing back together how a process actually ran. AI should help with this, and in a lot of cases it does, but most tools have a catch: the second they copy data out of a validated system, they break the compliance chain. You end up with something that looks great in a demo but can’t survive an audit, let alone a submission.

What we built together

The fix isn’t smarter AI on its own. It’s smart AI working from data you can actually trust.

Polar captures structured, contextualized data the moment it’s created and keeps it in one governed system. That’s the foundation. Our agents read from that governed data to draft CMC technical reports, clinical study reports, and submission dossiers, then hand each draft to a scientist to review and sign off. Every action, human or AI, lands in a 21 CFR Part 11 audit trail, so nothing falls out of compliance between the source data and the final submission.

Across customer deployments, teams have put documents like these together up to 70% faster with our agents.

“A regulatory filing that takes a team weeks, our agents draft in minutes, at submission-ready quality, with the compliance trail intact, because they work straight from governed data in Polar. That’s the difference between AI you can demo and AI you can take to submission.”

Anuj Chadha, Co-Founder, Alchemi

“Our mission is to accelerate life-changing therapies to patients, and as part of Danaher, that means turning ideas into impact with speed and certainty. IDBS delivers a governed data backbone that makes AI-ready data available across the biopharma lifecycle. By partnering with Alchemi, we can accelerate critical regulatory milestones using high-quality, compliant AI agents.”

Pietro Forgione, General Manager, IDBS

What’s next

This year, our agents will deliver at least 3,000 studies with top-five global CROs, large pharma, and biotech. Pairing Polar’s governed data with our agents means those teams don’t have to choose between moving fast and staying compliant.